- Report
- October 2024
- 198 Pages
Global
From €3235EUR$3,545USD£2,759GBP
€3595EUR$3,939USD£3,065GBP
- Report
- April 2025
- 274 Pages
Global
From €5339EUR$5,850USD£4,552GBP
- Report
- October 2024
- 250 Pages
Global
From €4517EUR$4,949USD£3,851GBP
- Report
- July 2024
- 145 Pages
Global
From €2282EUR$2,500USD£1,945GBP
- Report
- September 2024
- 250 Pages
Global
From €4517EUR$4,949USD£3,851GBP
- Report
- June 2024
- 200 Pages
Global
From €7255EUR$7,950USD£6,186GBP
- Report
- January 2022
- 60 Pages
Global
From €3605EUR$3,950USD£3,074GBP
- Report
- August 2023
- 90 Pages
Global
From €3500EUR$4,108USD£3,089GBP
The Chronic Fatigue Drug market is a subset of the Central Nervous System Drugs market. It includes drugs used to treat chronic fatigue syndrome (CFS), a condition characterized by extreme fatigue that cannot be explained by any underlying medical condition. These drugs are typically used to reduce fatigue, improve sleep, and increase energy levels. Commonly prescribed drugs include stimulants, antidepressants, and anti-inflammatory medications.
The Chronic Fatigue Drug market is highly competitive, with many companies offering products to treat CFS. Some of the major players in the market include GlaxoSmithKline, Pfizer, Merck, Novartis, and Sanofi. Other companies include AbbVie, AstraZeneca, and Johnson & Johnson. Show Less Read more
